Read the full stored bill text
SECOND REGULAR SESSION
HOUSE BILL NO. 2999
103RD GENERAL ASSEMBL Y
INTRODUCED BY REPRESENT A TIVE CA TO N.
6644H.01I JOSEPH ENGLER, Chief Clerk
AN ACT
T o repeal section 336.010, RSMo, and to enact in lieu thereof one new section relating to the
practice of optometry .
Be it enacted by the General Assembly of the state of Missouri, as follows:
Section A. Section 336.010, RSMo, is repealed and one new section enacted in lieu
2 thereof, to be known as section 336.010, to read as follows:
336.010. 1. The "practice of optometry" is the examination, diagnosis, treatment, and
2 preventative care of the eye, adnexa, and vision. The practice includes, but is not limited to:
3 (1) The examination of the eye, adnexa, and vision to determine the accommodative
4 and refractive states, visual perception, conditions, and diseases;
5 (2) The diagnosis and treatment of conditions or diseases of the eye, adnexa, and
6 vision;
7 (3) The performance of diagnostic procedures and ordering of laboratory and imaging
8 tests for the diagnosis of vision and conditions and diseases of the eye and adnexa;
9 (4) The prescription and administration of pharmaceutical agents, including
10 epinephrine delivery devices but excluding injectable agents, for the purpose of
11 examination, diagnosis, and treatment of vision and conditions or diseases of the eye and
12 adnexa;
13 (5) The performance of the following pro cedur es:
14 (a) The removal of superficial foreign bodies from the eye or adnexa;
15 (b) The r emoval of embedded for eign bodies fr om the eye or eyelid;
16 (c) The rem oval of corneal for eign bodies with or without a slit lamp and that
17 ar e equal to or less than one-third depth off the visual axis;
EXPLANA TION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is
intended to be omitted from the law . Matter in bold-face type in the above bill is proposed language.
18 (d) The rem oval of damaged or loose corneal epithelium without the use of a
19 blade;
20 (e) Epilation only by for ceps;
21 (f) The express ion of conjunctival follicles;
22 (g) The placement of punctal plugs;
23 (h) The placement of bandage contact lenses;
24 (i) The placement of self-r etaining amniotic membranes;
25 (j) Pr ocedur es rel ating to the tr eatment of blepharitis;
26 (k) Pr ocedur es rela ting to the trea tment of meibomian gland disease;
27 (l) The therapeutic rel ease of aqueous thr ough a pr eexisting wound; and
28 (m) The application of ultraviolet light for components of collagen cros slinking
29 or light adjustable lens;
30 (6) The employment of objective or subjective mechanical means to determine the
31 accommodative or refractive states of the human eye;
32 (7) The prescription or adaptation of lenses, prisms, devices, or ocular exercises to
33 correct defects or abnormal conditions of the human eye or vision or to adjust the human eye
34 to special conditions;
35 (8) The prescription and fitting of ophthalmic or contact lenses and devices;
36 (9) The prescription and administration of vision therapy; and
37 (10) The prescription and administration of low vision care.
38 2. An optometrist may not perform surgery , including the use of lasers for treatment
39 of any disease or condition or for the correction of refractive error .
40 3. As used in this chapter , except as the context may otherwise require, the following
41 terms mean:
42 (1) "Eye", the human eye;
43 (2) "Adnexa", all structures adjacent to the eye and the conjunctiva, lids, lashes, and
44 lacrimal system;
45 (3) "Board", the Missouri state board of optometry;
46 (4) "Diagnostic pharmaceutical agents", topically applied pharmaceuticals used for
47 the purpose of conducting an examination of the eye, adnexa, and vision;
48 (5) "Low vision care", the examination, treatment, and management of patients with
49 visual impairments not treatable by conventional eyewear or contact lenses and may include a
50 vision rehabilitation program to enhance remaining vision skills;
51 (6) "Pharmaceutical agents", any diagnostic and therapeutic drug or combination of
52 drugs that assist the diagnosis, prevention, treatment, or mitigation of abnormal conditions or
53 symptoms of the human eye, adnexa, and vision;
HB 2999 2
54 (7) "Therapeutic pharmaceutical agents", those pharmaceuticals, excluding injectable
55 agents, used for the treatment of conditions or diseases of the eye, adnexa, and vision;
56 (8) "V ision therapy", a treatment regiment to improve a patient's diagnosed visual
57 dysfunctions, prevent the development of visual problems, or enhance visual performance to
58 meet the defined needs of the patient.
✔
HB 2999 3